Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need.
The last earnings update was 46 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Mersana Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Mersana Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Mersana Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Mersana Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Mersana Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Mersana Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Mersana Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Mersana Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Mersana Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Mersana Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Anna Protopapas has been the Chief Executive Officer and President of Mersana Therapeutics, Inc. since March 2015. Ms. Protopapas has extensive strategic leadership experience and a demonstrated track record of results in the biopharmaceutical industry. She served as the President of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda since May 22, 2013 and served as its Chief Executive Officer since May 09, 2013, Senior Vice President of Corporate Development and Strategy since March 14, 2005, Member of the Leadership Team since January 2006 and Executive Officer since January 2006. During her tenure at Millennium, she had been a key driver in forging partnerships that have generated significant revenue and value for Millennium Pharmaceuticals Inc., including collaborations with Johnson & Johnson Pharmaceuticals Research and Development L.L.C., Aventis Pharmaceuticals and Abbott Laboratories. She joined Millennium in 1997 with diverse experiences ranging from business development to international marketing and chemical manufacturing. She served as an Executive Vice President of Global Business Development and Corporate Officer at Takeda Pharmaceuticals International, Inc. since June 24, 2011, where she was responsible for global acquisitions, partnering, licensing and venture investing. She served as an Executive Vice President at Takeda Pharmaceutical Company Limited and also served as the Head of Oncology Business from May 2013 to October 01, 2014 and Corporate Officer since June 24, 2011. Ms. Protopapas has been a Director of Dicerna Pharmaceuticals, Inc., since January 24, 2019. She served as Director of Bioverativ Inc. since March 2, 2017 until March 8, 2018, its sale to Sanofi. She has been Director of Mersana Therapeutics, Inc. since March 2015. She served as a Director of Ariad Pharmaceuticals, Inc. from April 28, 2015 to February 16, 2017. From October 1997 to October 2010, Ms. Protopapas served in various positions at Millennium Pharmaceuticals, including as the Senior Vice President of Strategy and Business Development, where she led the company's business development initiatives. She served as a Director of Ensemble Therapeutics Corporation (Formerly Ensemble Discovery Corporation). Ms. Protopapas holds bachelor's degree in Science and Chemical Engineering from Princeton University, a MS in Chemical Engineering from Massachusetts Institute of Technology and a Master's in Business Administration from Stanford University.
Anna's compensation has been consistent with company performance over the past year.
Anna's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Mersana Therapeutics management team is about average.
Senior VP & Chief Scientific Officer
Chief Financial Officer
Executive Director of Investor Relations & Corporate Communications
Chief Business Officer
Senior Vice President of Chemistry
Chief Medical Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Mersana Therapeutics board of directors is less than 3 years, this suggests a new board.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.